- ￥390 - 700
- MedChemExpress(MCE)
- 美国
- HY-17356
- 2025年07月15日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
Powder: -20°C, 3 years; 4°C, 2 years. In solvent: -80°C, 6 months; -20°C, 1 month.
- 库存：
货期：1-2天
- 供应商：
MedChemExpress LLC
- CAS号：
49562-28-9
- 规格：
10 mM * 1 mL/200 mg/5 g/10 g
| 规格： | 10 mM * 1 mL | 产品价格： | ￥550.0 |
|---|---|---|---|
| 规格： | 200 mg | 产品价格： | ￥390.0 |
| 规格： | 5 g | 产品价格： | ￥500.0 |
| 规格： | 10 g | 产品价格： | ￥700.0 |
MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。
Fenofibrate
CAS No. : 49562-28-9
MCE 国际站：Fenofibrate
产品活性：Fenofibrate 是一种选择性的 PPARα 激动剂，EC50 为 30 μM。Fenofibrate 抑制细胞色素 P450 亚型, 对 CYP2C19，CYP2B6，CYP2C9，CYP2C8 和 CYP3A4 的 IC50 分别为 0.2，0.7，9.7，4.8 和 142.1 μM。
研究领域：Vitamin D Related/Nuclear Receptor | Cell Cycle/DNA Damage | Metabolic Enzyme/Protease | Autophagy
作用靶点：PPAR | Cytochrome P450 | Autophagy
In Vitro: Fenofibrate is a relatively potent inhibitor of CYP2B6 (IC50=0.7±0.2 μM) and CYP2C19 (IC50=0.2±0.1 μM). Fenofibrate is also a moderate inhibitor of CYP2C8 (IC50=4.8±1.7 μM) and CYP2C9 (IC50=9.7 μM). Fenofibrate binds to and inhibits cytochrome P450 epoxygenase (CYP)2C with higher affinity than to PPARα. Fenofibrate is a well-known PPARα agonist, but an in vitro assessment of 209 frequently prescribed drugs and related xenobiotics suggests that Fenofibrate is also a potent inhibitor of cytochrome P450 epoxygenase (CYP)2C. The affinity of Fenofibrate to CYP2C is >10 times higher (EC50=2.39±0.4 μM) than to PPARα (EC50=30 μM). Fenofibrate at a low dose inhibits CYP2C8 activity without PPARα activation.
In Vivo: Daily intake of Fenofibrate at this low dose (10 μg/g/day) inhibits retinal and choroidal neovascularization induced by CYP2C8 overexpression by 29% (P=0.021) and 36% (P=1.2×10−9) respectively.
相关产品：Drug Repurposing Compound Library Plus | FDA-Approved Drug Library Plus | FDA-Approved Drug Library Mini | Bioactive Compound Library Plus | Cell Cycle/DNA Damage Compound Library | Metabolism/Protease Compound Library | FDA-Approved Drug Library | Anti-Cancer Compound Library | Antiviral Compound Library | Autophagy Compound Library | Anti-Aging Compound Library | Drug Repurposing Compound Library | Antioxidant Compound Library | Anti-diabetic Compound Library | Oxygen Sensing Compound Library | Anti-Cardiovascular Disease Compound Library | NMPA-Approved Drug Library | Orally Active Compound Library | FDA Approved & Pharmacopeial Drug Library | Drug-Induced Liver Injury (DILI) Compound Library | Mitochondria-Targeted Compound Library | Transcription Factor-Targeted Library | Lipid Metabolism Compound Library | Rare Diseases Drug Library | Children’s Drug Library | Antidepressant Compound Library | EMA-Approved Drug Library | FDA-Approved Anticancer Drug Library | Human Metabolite Library | Nuclear Receptor Compound Library | Non-steroidal Anti-Inflammatory Compound Library | Anti-Aging Natural Product Library | Off-patent Drug Library | Mitochondrial Protection Compound Library | Mitochondrial Toxicity Compound Library | Highly Selective Inhibitors Library | Highly Selective Activators Library | Cell Death Library | Retinoic acid | Rosiglitazone | GW9662 | Verapamil | Pioglitazone | Apigenin | GW6471 | Fisetin | Chlorpromazine hydrochloride | T0070907 | Pirinixic acid | Ketoconazole | 1-Aminobenzotriazole | Letrozole | Abiraterone | 5-Aminosalicylic Acid | Troglitazone | Itraconazole | Cepharanthine | GW 501516 | Quinidine (15% dihydroquinidine) | Daidzein | Icariin | Diosmetin | Astaxanthin | Clarithromycin | Lanifibranor | GW7647
热门产品线：重组蛋白 | 化合物库 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物
Trending products：Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Dye Reagents | PROTAC | Isotope-Labeled Compounds
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验特(fenofibrate) 片剂，100mg/次，3次/日，饭后服。 环丙贝特(ciprofibrate)片剂，开始100mg/次，可增至200mg/次，1次/日。 乐伐他汀(lovastatin)片剂，20～40mg/次，1次/日，晚餐时服，必要时4周内可增至80mg/次，1次/日。 普伐他汀(pravastatin) 片剂，5～10mg/次，2次/日。 塞伐他汀(simvastatin) 片剂，10mg/次，1次/日。 普罗布考(probucol) 片剂，250～500mg
非诺贝特(fenofibrate) 片剂，100mg/次，3次/日，饭后服。 环丙贝特(ciprofibrate)片剂，开始100mg/次，可增至200mg/次，1次/日。 乐伐他汀(lovastatin)片剂，20～40mg/次，1次/日，晚餐时服，必要时4周内可增至80mg/次，1次/日。 普伐他汀(pravastatin) 片剂，5～10mg/次，2次/日。 塞伐他汀(simvastatin) 片剂，10mg/次，1次/日。 普罗
酸类药效强毒性低，有吉非贝齐（gemfibrozil），苯扎贝特（bezafibrate）、非诺贝特（fenofibrate）、环丙贝特（ciprofibrate）等。 【药理作用】口服后，能明显降低病人血浆TG、VLDL、IDL含量，而使HDL升高。对LDL作用与患者血浆中TG水平有关。对单纯高甘油三酯血症患者的LDL无影响，但对单纯高胆固醇血症患者的LDL可下降15%。此外，本类药物也有抗血小板聚集、抗凝血和降低血浆粘度，增加纤溶酶活性等作用。 降低血浆TG、VLDL、IDL作用
技术资料暂无技术资料 索取技术资料
